Adults aged more than 70 who received more prescriptions for nirmatrelvir-ritonavir did not show decreased rates of ...

The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to ...

The authors compared outcomes among adults just under 70 years who were not prescribed Paxlovid to those who were given the ...

Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as ...

For a majority of people, the COVID vaccine doesn’t cause adverse health effects — but a small percentage experience chronic ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

The finding that the vaccines substantially reduce the risk of long COVID in kids echoes findings seen in studies on adults.

Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...